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Abstract: The outcome of host-virus interactions is determined by a number of factors, some related
to the virus, others to the host, such as environmental factors and genetic factors. Therefore, different
individuals vary in their relative susceptibility to infections. Human cytomegalovirus (HCMV) is an
important pathogen from a clinical point of view, as it causes significant morbidity and mortality
in immunosuppressed or immunosenescent individuals, such as the transplanted patients and the
elderly, respectively. It is, therefore, important to understand the mechanisms of virus infection
control. In this review, we discuss recent advances in the immunobiology of HCMV-host interactions,
with particular emphasis on the immunogenetic aspects (human leukocyte antigens, HLA; killer cell
immunoglobulin-like receptors, KIRs; immunoglobulin genetic markers, GM allotypes) to elucidate
the mechanisms underlying the complex host-virus interaction that determine various outcomes
of HCMV infection. The results, which show the role of humoral and cellular immunity in the
control of infection by HCMV, would be valuable in directing efforts to reduce HCMV spurred
health complications in the transplanted patients and in the elderly, including immunosenescence.
In addition, concerning GM allotypes, it is intriguing that, in a Southern Italian population, alleles
associated with the risk of developing HCMV symptomatic infection are negatively associated
with longevity.
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1. Introduction
Both environmental and genetic factors, as well as factors related to viruses, play a key role in
determining the outcome of viral infections. Therefore, different individuals vary in their relative
susceptibility to infections [1]. Regarding the genetic component of the response to viruses, the genes
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involved are polymorphic most likely because of Darwinian selection. Indeed, as suggested for the
first time by J.B.S. Haldane, the main infectious diseases were the most important selective forces in
shaping our evolutionary history [2].
It is well known that human cytomegalovirus (HCMV) is an important pathogen from a clinical
point of view, because it causes significant morbidity and mortality in immunosuppressed individuals
such as the transplanted patients and the elderly, in turn exacerbating their immunosenescence [3,4].
It is, therefore, important to understand the underlying mechanisms of virus infection control.
HCMV is a member of the herpes virus family (type 5) that is ubiquitous in human populations.
HCMV, the largest human virus, has 235 Kb, double-stranded linear DNA genome. HCMV is
transmitted from human to human. There is no animal reservoir. The transmission occurs via
saliva, urine, breastfeeding, placenta, sexual intercourse, blood and organ transplants. In transplanted
patients, immunosuppressive drugs can increase the risk of infection and complications [4–7].
Clinically, primary HCMV infection is asymptomatic in the 90% of the infected and
immunocompetent population. Symptomatic primary HCMV infection of the adolescent or adult
usually results in a mononucleosis-like syndrome with malaise, fever, sweating, and abnormal liver
function [8]. In any case, a latent infection that lasts a lifetime is established. In a review of literature,
seroprevalence was found to range from 45% to 100%, being the highest in South America, Africa and
Asia and the lowest in Western Europe and United States. Worldwide, seroprevalence among whites
tended to be 20–30 percentage points lower than that of Caucasians. Persons of higher socioeconomic
status were more likely to be HCMV seronegative. In addition, seroprevalence increases with age,
reaching more than 85% by 80 years. Although in most studies the differences were small, men
generally had lower seroprevalences than women [3,7,9,10].
Most people carry the virus in a latent form and are at risk of reactivation. HCMV infection
establishes a long-lasting immunity (but HCMV is able to manipulate the immune system) that
limits the replication of virus after reactivation from latency. The reactivation mostly occurs both in
immunosuppressed patients (as those transplanted) and in immunocompromised patients (septic
patients or elderly) [11,12]. All these conditions are characterized by an inflammatory state, and it has
been suggested that inflammation can be responsible for reactivation [13].
Pattern recognition receptors such as Toll-like receptors recognize components of the virion,
thereby triggering the innate immune response to the virus with the production and/or release
of pro-inflammatory cytokines that in turn recruit and activate cells of innate immunity, including
Natural Killer (NK) cells that destroy target cells infected by HCMV. There is also triggering of
acquired immunity that involves both T and B lymphocytes. It results in a large cytotoxic CD8 T
cell response that plays a key role in the control of primary HCMV infection and reactivation from
latency. In addition, T helper CD4 lymphocytes, through the production of interferon-γ and their
helper function for CD8 and B lymphocytes, play a role in the control of HCMV infection [14]. Due to
coevolution within their hosts for millions of years, herpes viruses, including HCMV, are able to
encode several proteins and microRNAs responsible for evading the host immune response, both
during lytic infection and during latency. It allows HCMV to replicate and disseminate in the face
of a competent immune system and to establish latency with periodical viral reactivation and virus
shedding through the life of the host. HCMV products are, indeed, able to inactivate complement
cascade, to mitigate the effects of interferon and to prevent apoptosis of infected cells. Other virus
products are proteins homologue for cytokines, chemokines and their receptors as well as for fragment
crystallisable γ receptor (FcγR). Lastly, virus products interfere with T and NK cells functions. [15,16].
HCMV is not only a master in immune evasion but also is responsible for the manipulation of
immune system with ageing. In the latent state, the intermittent production of viral antigens prevents
contraction of virus-specific T cells. Thus, a large population of HCMV-specific CD8+, and to a lesser
extent, CD4+ T cells, is generated. That is responsible for the phenomenon of memory cell inflation
leading to the emergence of vast populations of resting effector CD8+ and CD4+ cells. In the elderly,
many alterations of innate and acquired immunity have been described and viewed as deleterious,
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hence the term immunosenescence [17]. Age, followed by sex and the HCMV status, has the greatest
impact on the immune system. HCMV is considered to contribute to shape the immune profile and
function during normal human ageing. Accordingly, modulation of the immune response by HCMV
may occur, resulting in less effective control of HCMV replication following virus reactivation [3,15,18].
However, inflationary CD8+ cells, after proper activation stimuli, can divide, secrete cytokines, and
execute cytolysis, i.e., they are not exhausted. The production of inflammatory cytokines can contribute
to the pro-inflammatory status of ageing, called inflamm-ageing [17]. Moreover, there is some evidence
of a slight loss of control of HCMV replication in the elderly compared with younger people, as the
HCMV load within blood increases markedly in healthy people over the age of 70 years [19]. There is
some evidence of an association of HCMV seropositivity with increased mortality from cardiovascular
disease, as a result of damage caused by the large expansion of cytotoxic CD4+CD28-negative T cell
populations commonly seen in HCMV-infected individuals [20,21]. Immune changes associated with
HCMV may have significant impact during co-infection and vaccination as well as on fitness [22,23].
Herpes virus latent infection should contribute to immune dysfunction in the elderly but may be
beneficial during childhood-adult years [15,18].
In our review, we discuss recent advances in the immunogenetic control of HCMV-host
interactions. We will focus on the role played by human leukocyte antigens (HLA) responsible
for both humoral and cellular control, killer cell immunoglobulin-like receptors (KIRs), responsible
for cellular control, after interaction with class I HLA, and γ marker (GM) immunoglobulin allotypes
responsible for humoral control. Almost all of the papers concern the immunogenetic control of HCMV
reactivation in transplanted patients. Data are also discussed considering the role of HCMV in ageing
and immunosenescence.
2. HLA and HCMV
The HLA system encodes cell-surface proteins responsible for the regulation of the immune
system. HLA genes are highly polymorphic, i.e., they have many different alleles, involved in
fine-tuning of the acquired immune responses. HLA classes have different functions [24–26]. (I) Class
I (HLA-A, -B and -C) presents peptides from inside the cell to the surface of the cell, including viral
fragments if the cell is infected by a virus. It follows that the cell can be lysed by CD8+. (II) Class II
(HLA-DRA, HLA-DRB1, HLA-DRB3–5, HLA-DQA, HLA-DQB, HLA-DPA and HLA-DPB) presents
peptides from outside the cell to CD4+ cells, which in turn stimulate B lymphocytes to produce
antibodies to that specific antigen. (III) Class III encodes components of the complement system
and pro-inflammatory cytokines. The high polymorphism of class I and II molecules affects the
peptide-binding groove, since it varies the amino acids sequences that can be housed within the
peptide-binding pockets. Different HLA alleles possess different peptide-binding repertoires and it
is difficult for disease-related proteins to escape detection. Therefore, it is not surprising that several
infectious and autoimmune diseases are associated with different HLA antigens, responsible for
different humoral or cellular immune responses [24–26]. However, in the last few years, it is becoming
clear that Class I antigens can play a role as ligand for KIR. Therefore, several observed association of
HLA class I antigen with infectious and autoimmune diseases can be explained by their role as ligands
for KIR [26].
As mentioned previously, HCMV interferes with immune responses at different levels. Several
proteins (or microRNA) produced by the virus can interfere with the functions of Class I and Class II
molecules, i.e., antigen processing and presentation, e.g., they can induce their down regulation or
their degradation [15,16].
Concerning the role of HLA in the control of HCMV infection, most studies regard HCMV
infection/reactivation in patients after kidney transplantation. However, as reported by Futohi et al. [6]
the results have been discordant. Therefore, no conclusion can be drawn from these studies, although
in three papers out of eight an association with HLA-DR7 was reported [27–29].
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As discussed by Caruso et al. [24], several methodological problems can explain the discrepancies
observed in studies concerning association of HLA with diseases as follows. (I) Insufficient sample
sizes to detect differences in HLA antigen frequencies. (II) Different inclusion with inappropriate
mixing of data (cohort effect) and inappropriate control matching, i.e., lack of selection from the same
target population. (III) The different genetic background of studied population. (IV) The lack of
Bonferroni’s correction for multiple comparisons.
However, in the previously quoted study [6], the presence of HLA-B8 allele had a protective
effect for developing HCMV infection after kidney transplantation. It is intriguing that in a study
performed on HCMV infection in Ireland, HLA-A1, HLA-B8 alleles were associated with HCMV
seronegativity [5]. These alleles are carried by the 8.1 ancestral haplotype, i.e., an evolutionarily
highly conserved haplotype, known to influence cytokines production with decreased type 1 responses
in contrast to type 2 ones. It follows that humoral responses are enhanced in people carrying this
haplotype [30].
These results are of some importance for the relationship between HCMV and ageing. In fact, this
haplotype has been associated with male longevity [24,25], hence this datum strengths the suggestion
of the detrimental role for HCMV in achieving successful ageing.
3. KIR and HCMV
KIRs, expressed on the membrane of NK cells and a minority of T lymphocytes, regulate the
killing function of these cells by interacting with specific amino acid motifs, public epitopes, carried by
some HLA class I molecules, and expressed on their targets. They are characterized by two or three
extracellular domains and a short (S) or long (L) intracytoplasmic tail that respectively transduces
either activating or inhibitory signals (see Figure 1). The KIR gene complex is characterized by multiple
gene-content haplotypes, i.e., it is polygenic. KIR genes are organized in two basic haplotypes defined
on the basis of gene content, and are termed A and B. Group A haplotypes are characterized by
the absence of the following genes KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1,
whereas group B haplotypes are characterized by the presence of one or more of the previous genes.
Thus, the B haplotypes have more genes encoding activating KIR than A haplotypes. Moreover, KIR
genes exhibit allelic variability, i.e., they are polymorphic. Furthermore, KIR expression on NK cells is
stochastic, resulting in a significant variation of the NK cell repertoire among individuals and among
populations. KIRs are able to detect cells infected by viruses or transformed, by binding the different
class I allelic variants. Most inhibitory KIRs specifically recognize sets of HLA class I alleles; yet,
the ligands for some of them and for most activating KIRs are unknown. Specific combinations of KIRs
with their cognate HLA ligands have been associated with infectious diseases, autoimmune disorders,
pregnancy outcomes and cancer. In addition, they are crucial in determining clinical outcomes of both
hematopoietic stem cell and solid organs transplantation [31–34].
There is compelling evidence that NK cells play a crucial role in host defence against HCMV
infection. Thus, it is not unexpected the interference by proteins or microRNA coded by HCMV
with NK function. As an example, several proteins affect the expression of ligands of the NKG2D
receptor, a transmembrane protein encoded by KLRK1 activating gene (not linked to KIR genes)
whose ligands are induced-self proteins completely absent or present at low levels on the surface of
normal cells, but overexpressed in infected or transformed cells [35]. Clearly, the degradation or the
down regulation of HLA Class I antigens, previously reported, interferes with KIR [15,16]. However,
as shown in Figure 1, these antigens can bind both activating and inhibitory KIRs.
The entire population of NK cells from a child with a novel immunodeficiency syndrome and
recurrent HCMV infection expressed the KIR2DL1, with inhibitory function. Since the patient also
possessed the KIR2DL1 ligand group, HLA-C2, it was suggested the possibility that the strong
inhibitory KIR2DL1/HLA-C2 combination impaired NK cell activity and prevented the cells from
mounting a protective response against HCMV [36].
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Figure 1. The figure shows the killer cell immunoglobulin-like receptor (KIR)/ human leukocyte
antigens (HLA) interaction with inhibitory or activating effects. The activating receptors (
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after transplantation. In fact, patients carrying more than one activating KIR gene (KIR BA or BB
genotypes) showed a rate of infection d reactiv tion si nificantly lesser (20%) than that observed in
patients with a KIR AA genotype (36%) (with KIR2DS4 as only activating KIR). Moreover, the number
of activating KIR genes correlated with the degree of protection. This study supports a role for
activating KIR in the control of HCMV infection after kidney transplantation [37]. The KIR/HLA
genotypes and the rate of HCMV infection was analysed in 196 kidney transplant recipients. In kidney
recipients, it was shown that, after tra spl ntati n, both the presence f activating KIR ge es and the
absence of the HLA-C ligands for inhibitory KIR were associated with a lower rate of HCMV [38].
After hematopoietic stem cell transplantation, whether the donor had either ≥5 activating KIR genes
or KIR2DS2 and KIR2DS4 genes, there was a low risk of HCMV r activation in the recipient [39].
Finally, in stem cell transplantatio s involving siblings where both donor and recipient w re HCMV
seropositive and the donor possessed a copy of the KIR haplotype B, the reactivation rate was 28%,
whereas the HCMV reactivation rate was 65% if donor was homozygous for the KIR A haplotype, i.e.,
with only one activati g KIR. A signific nt decreased risk f HCMV reactivatio was also confirmed
by multiv riat nalysis if the donor had more than one activating KIR gen [40]. All these results
obtained in transplanted patients demonstrate the importance of activating KIRs in the immune
surveillance against HCMV.
Interestingly, similar data were btained in immunocompetent subjects, studying a cohort of 120
subjects with HCMV inf ction [41]. Indeed, evidence has been provided for a detrimental effect of the
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AA haplotype or the HLA-Bw4T group on the outcome of primary HCMV disease. The frequency of the
homozygous A haplotype was higher in symptomatic patients than in controls. By logistic regression,
the risk of developing symptomatic disease was associated with the homozygous A haplotype and
the HLA-Bw4T groups. These results show the key role played by KIR/HLA polymorphisms in
the immunocompetent host, suggesting that HLA-Bw4T group exerts its function by binding the
inhibitory KIR3DL1 gene. With the aim to gain insight in the association of this combination and
HCMV, our group analysed the distribution of HLA-B alleles, in symptomatic patients carrying
HLA-Bw4T group. We observed (Table 1) that, in symptomatic patients carrying HLA-Bw4T group,
HLA-B*44 allele was over-represented, 55.6%, whereas its frequency in Sicily is 8.9% [42]. This result is
intriguing since this allele is in linkage disequilibrium with HLA-DR7 [43], reported to be associated
with infection/reactivation in patients after kidney transplantation [27,29].
Table 1. Distribution of HLA-B alleles in Human cytomegalovirus (HCMV) symptomatic patients
positive for the different HLA-Bw4 groups. (The number of alleles is twice the number of subjects,
as each person has two alleles—one maternal and one paternal).
HLA-Bw4 Groups HCMV Patients (N = 31)
N %
HLA-Bw4T
B*44 11 33.30
B*13 4 12.12
B*35 3 9.09
B*14 1 3.03
B*40 1 3.03
B*27 2 6.06
B*73 1 3.03
B*50 1 3.03
B*07 0 0
B*18 0 0
HLA-Bw4I
B*27 1 3.03
B*14 1 3.03
B*39 1 3.03
B*57 3 9.09
B*35 5 15.15
B*38 2 6.06
B*40 1 3.03
B*49 3 9.09
B*50 2 6.06
B*08 1 3.03
B*15 1 3.03
B*51 4 12.12
B*67 1 3.03
B*18 0 0
B*53 1 3.03
B*58 3 9.09
B*44 1 3.03
B*52 1 3.03
HLA-Bw4T/HLA-Bw4I
B*44 4 12.12
B*13 0 0
B*49 1 3.03
B*53 1 3.03
Genomic DNA was extracted by a commercial kit (PureLink®® Genomic DNA, ThermoFisher Scientific, Waltham,
MA, USA) from frozen mononuclear cells obtained in the previous study [41] from peripheral whole blood samples.
The HLA-B loci genotypes were determined using the commercially available HLA Class I B Locus DNA Typing
Tray kit (One Lambda, ThermoFisher Scientific Brand, California, USA), according to the manufacturer instructions.
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Finally, the correlation of KIR gene distribution and the anti-HCMV antibody titer has been
studied in the elderly. Analysis of the distribution of KIR genes showed a non-significant decreased
frequency of inhibitory KIR2DS5 gene in the group with higher (>20 IU/mL) HCMV-specific IgG
antibody levels [44,45]. Therefore, a study in a larger group of elderly is warranted.
4. GM Allotypes and HCMV
The term allotype refers to any genetic variant of a protein. In immunology, GM allotypes indicate
allelic hereditary variants, encoded by autosomal codominant alleles that follow Mendelian laws of
heredity, expressed on immunoglobulin constant region of γ1, γ2 and γ3 chains. GM allotypes are
encoded by three very closely linked, highly homologous, immunoglobulin heavy gamma (IGHG)
genes, on chromosome 14q32. Linkage disequilibrium in the GM system within an ethnic group is
almost absolute and the determinants are transmitted as a group, i.e., haplotype. Each major ethnic
group has a distinct array of several GM haplotypes [46,47].
These observations point towards a role for differential selection in the maintenance of GM
polymorphism. Many lines of evidence point towards infectious diseases as the principal selective
forces of natural selection [2]. GM allotypes have been shown to be associated with immunity to many
infectious pathogens. They also influence the chance for survival from epidemics, such as typhoid and
yellow fever [48]. Different mechanisms have been proposed to explain these associations [49].
There are inter individual differences in the level of anti-HCMV IgG antibodies, suggesting the
existence of host immune response genes for this trait [50]. However, a genome-wide association
study (GWAS) found no major genes for anti-HCMV antibody responsiveness [51]. As pointed out
elsewhere [52,53], current GWAS do not evaluate GM genes because they are not included in the
commonly used genotyping arrays. The extensive homology of IgG gene segments expressing various
GM allotypes may have contributed to their exclusion from these arrays. Therefore, it is necessary
to employ a candidate gene approach for evaluating the role of GM genes in the immunobiology of
HCMV infection.
Using a candidate gene approach, the contribution of GM allotypes to the magnitude of antibody
responses to HCMV glycoprotein B (gB), which is required for viral infectivity and is a major component
of the viral envelope, was investigated. Results showed that two allotypes at the γ1 locus, GM3 and
GM17, additively contributed to the level of IgG antibodies to gB. The homozygosity for the GM 17
allotype was associated with high, while the homozygosity for its allelic counterpart (GM 3) with
low, anti-HCMV gB antibody levels, respectively. The heterozygotes exhibited intermediate levels of
antibodies. GM 5 and GM 21 allotypes, which are in linkage disequilibrium with GM 3 and GM 17
allotypes, respectively, followed a similar pattern of anti-HCMV gB antibody responses [50].
Several mechanisms could account for the GM gene involvement in humoral immunity to
HCMV: structural contribution to the idiotypes involved in HCMV immunity, contribution to the
conformational modifications of antibody binding sites that could influence its affinity, and linkage
disequilibrium of constant-region GM allotypes with the variable-region genes. Murine studies
have clearly shown that differences in the amino acid sequences in the constant region affect the
secondary structure of the antigen-binding site in the variable region. Amino acid substitutions
that characterize GM allotypes cause structural changes in the constant region, which could impose
structural constraints (conformation) on the variable region, resulting in variation in antibody affinity
to HCMV. Thus, isotype restriction of antibodies to HCMV, which are predominantly IgG1 and IgG3,
may reflect structural constraints imposed by the constant-region allotypes on the variable-region
binding [46,49,54].
As previously stated, the HCMV has developed a large repertoire of highly sophisticated
strategies, directed against almost every component of the human immune system, for evading host
immunosurveillance [15,16]. One of these strategies involves the generation of three proteins, encoded
by genes TRL11/IRL11, UL119-UL118 and RL13 that have functional properties of the FcγR [16,55].
The viral FcγRs essentially neutralize the constant region of anti-HCMV IgG antibodies that are
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involved in effector functions, such as antibody-dependent cellular cytotoxicity, antibody-dependent
cellular phagocytosis and complement-dependent cellular cytotoxicity. This helps the virus to evade
host immunosurveillance. GM allotypes have been shown to modulate this viral immunoevasion
strategy. IgG1 proteins expressing the haplotype carrying GM3 allotype had significantly higher affinity
for the TRL11/IRL11-encoded decoy FcγR than IgG1 expressing the haplotype carrying GM17 allotype.
In contrast, the UL119-UL118-encoded FcγR has higher affinity for the IgG1 proteins expressing the
GM17 haplotype than those expressing the GM3 haplotype. The affinity of the RL13-encoded FcγR to
the allotypically disparate IgG1 proteins follows a similar pattern [56–58].
An interaction between HLA/KIR genes and GM allotypes in the control of HCMV infection was
shown in Sicilian population. Particularly, it was shown the association of GM17/17 with the risk of
developing symptomatic infection with a gene–dose effect, i.e., the association was observed only in
homozygous people. The risk of symptomatic infection was also shown in people carrying GM23,
without evidence of a gene–dose effect. In addition to these GM allotypes, HLA-C2 and HLA-Bw4T
groups remained independently associated with the risk of HCMV symptomatic infection in a multiple
logistic regression analysis. Therefore, both a possible epistatic interaction of GM allotypes with HLA
gene variants, and an independent effect of these GM allotypes can be hypothesized [59]. These results
are not in contrast with the above reported association of GM17 allotype with an increased antibody
response to HCMV [50], because this increased response should depend on a less efficient control of
HCMV that determines a greater antigenic stimulation.
Regarding the relationship between HCMV and ageing, it is noteworthy that, in another Southern
Italy population, GM3 allotype, the alternative allele of GM17, was significantly overrepresented
in long-living individuals [60], strengthening the suggestion of the detrimental role for HCMV in
achieving successful ageing.
To confirm and extend these observations, large scale studies involving GM allotypes and
anti-HCMV antibodies should be conducted in long-living individuals and young controls.
5. Summary
Considering the profound effects of HCMV infection on health and the quality of life of
immunosenescent individuals—either transplanted patients or old subjects—the identification
of the mechanisms responsible for the immunogenetic control of HCMV infection should have
important clinical implications. Therefore, the data discussed on the role of humoral and cellular
immune responses in the control of HCMV infection are important in driving efforts to reduce the
HCMV-associated health complications in old subjects and in transplanted patients. Further efforts
in determining the crucial role of HLA, KIR and GM genes in HCMV control will greatly enhance
our understanding of the immunogenetic aspects of HCMV infections, and to potentially apply
this knowledge clinically, i.e., in the development of new vaccines and in the identification of new
therapeutic targets.
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